Probiotics as a Novel Approach to Modulate Gut Hormone Secretion and Risk Factors of Type 2 Diabetes and Complications
Launched by GERMAN DIABETES CENTER · Nov 29, 2010
Trial Information
Current as of June 12, 2025
Unknown status
Keywords
ClinConnect Summary
Prediabetes and diabetes are accompanied by insufficient gut hormone release, insulin resistance, insufficient insulin secretory capacity and low grade systemic inflammation. Results of recent animal experiments suggest that ingestion of probiotics not only influences gut microbiota composition and intestinal permeability but also secretion of GLP-2 as well as insulin resistance, components of metabolic syndrome and diabetes development. GLP-2 secretion has been suggested to be a key mediator of probiotic effects mediating decreased intestine permeability through binding to intestinal GLP2 ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Obese subjects: age 40 - 65 years, obesity (BMI 30-45 kg/m2), non-smoking, absence of gastrointestinal disease, willingness to abstain from intake of fermented milk products over a study period of 8 weeks.
- • Healthy control subjects: non-obese (BMI 19-25 kg/m2), non-diabetic subjects, matched for age and sex, non-smoking, absence of gastrointestinal disease, willingness to abstain from intake of fermented milk products over a study period of 8 weeks.
- Exclusion Criteria:
- • pregnancy, cancer, chronic diseases, antibiotic therapy, competitive athletes.
About German Diabetes Center
The German Diabetes Center (Deutsches Diabetes-Zentrum, DDZ) is a leading research institution dedicated to advancing the understanding, prevention, and treatment of diabetes and its related complications. As a prominent sponsor of clinical trials, the DDZ integrates cutting-edge scientific research with clinical practice, focusing on innovative therapeutic strategies and patient-centered care. With a commitment to excellence, the center collaborates with national and international partners to facilitate groundbreaking studies that aim to improve health outcomes for individuals affected by diabetes. Through its robust infrastructure and expertise, the German Diabetes Center plays a crucial role in shaping the future of diabetes research and management.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Düsseldorf, Duesseldorf, Germany
Patients applied
Trial Officials
Nanette C Schloot, Priv.-Doz. MD
Principal Investigator
German Diabetes Center, Duesseldorf
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials